Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207963 | 1.00 | CA1 (0.60) | CA1CA2LMNAHTTMAPT | |
| SCHEMBL10159191 | 0.85 | GSK3B (0.52) | CA1CA2LMNAHTTMAPT | |
| SCHEMBL29391618 | 0.82 | ERCC5 (0.61) | CA1CA2LMNAMAPTMEN1 | |
| SCHEMBL404490 | 0.82 | ERCC5 (0.61) | CA1CA2LMNAMAPTMEN1 | |
| SCHEMBL11804367 | 0.82 | CA1 (0.62) | CA1CA2LMNAHTTMAPT | |
| SCHEMBL1154685 | 0.82 | MAPK1 (0.63) | CA1CA2LMNAHTTMAPT | |
| SCHEMBL9635504 | 0.82 | CA1 (0.62) | CA1CA2LMNAHTTMAPT | |
| SCHEMBL9115251 | 0.81 | LMNA (0.55) | CA1CA2LMNAHTTMAPT | |
| SCHEMBL19667457 | 0.81 | CA1 (0.60) | CA1CA2LMNAHTTMAPT | |
| SCHEMBL3930687 | 0.81 | GSK3B (0.52) | CA1CA2LMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109890797-B | Substituted carbon nucleoside derivatives useful as anticancer agents | 辉瑞公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2019-09-10 | — | — | US | disclosed |
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | OHIO UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3464249-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-6737434-B2 | HAVING ACTIVITIES ANALOGOUS TO THOSE EXHIBITED BY GRANULOCYTE-COLONY STIMULATING FACTOR; FOR THERAPY OF IMMUNE DISEASES WHICH ACCOMPANY REDUCTION IN NEUTROPHILS CAUSED BY CHEMOTHERAPY OR RADIOTHERAPY OF CANCER | SSP CO., LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| US-20030176482-A1 | Imidazole derivatives or their salts | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1319658-A1 | IMIDAZOLE DERIVATIVES OR THEIR SALTS | SSP Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-4602022-A | VASODILATORS, ANTIAGGREGANT AGENTS, ANTIINFLAMMATORY AND HYPOTENSIVE AGENTS | FARMITALIA CARLO ERBA, S.P.A. (IT) | 1986-07-22 | — | — | US | disclosed |
| US-4510149-A | VASODILATORS, HYPOTENSIVE AGENTS, ANTIARTHRITIC AGENTS | FARMITALIA CARLO ERBA S.P.A. (IT) | 1985-04-09 | — | — | US | disclosed |
| US-4342775-A | FOR USE AS ANTICOAGULANT AND REDUCING SERUM SHOLESTEROL OR SERUM TRIGLYCERIDES | FARMITALIA CARLO ERBA S.P.A. (IT) | 1982-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176482-A1 | Imidazole derivatives or their salts | CSF3R, CSF1R, FLT3 | CA1 4201/4885CA2 3311/4885LMNA 4229/4885 |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | CA1 2217/4885CA2 2263/4885LMNA 452/4885 |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | CA1 2217/4885CA2 2263/4885LMNA 452/4885 |
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | FABP1, LIPC, SLC10A1 | CA1 3366/4885CA2 3093/4885LMNA 1257/4885 |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | CA1 4871/4885CA2 3861/4885LMNA 3406/4885 |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | CA1 2217/4885CA2 2263/4885LMNA 452/4885 |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | CA1 4870/4885CA2 3847/4885LMNA 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.